Can-Fite BioPharma Ltd.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company incorporated in September 1994 and headquartered in Ramat Gan, Israel. It develops orally bioavailable small-molecule drugs targeting the A3 adenosine receptor (A3AR) for oncology, inflammatory diseases, liver conditions, and erectile dysfunction. Its lead candidates include Piclidenoson for psoriasis (Phase III) and Namodenoson for liver cancer (Phase III). The company maintains an advanced pipeline and has received regulatory clearances from the FDA and EMA for pivotal trials.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Secured $8.3M via private placement to support operations.
- Piclidenoson and Namodenoson advancing in Phase III trials for psoriasis and liver cancer.
- Platform technology targets A3AR for multiple indications including NASH and erectile dysfunction.
- Received FDA and EMA clearance for pivotal psoriasis trial.
Ask StreetZero about Can-Fite BioPharma Ltd.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account